U.S. pharma giant copyright scrapped two experimental weight loss drugs past year—a when-every day capsule, lotiglipron, as a result of elevated liver enzymes in addition to a 2 times-each day tablet, danuglipron, resulting from strong Unwanted side effects—but CEO Albert Bourla has